NMN vs. NR: The NAD+ Precursor Battle — What the Latest Human Trials Actually Show
NAD+ — nicotinamide adenine dinucleotide — is one of the most important molecules in aging biology. Its decline with age is among the most consistent findings in the field. But the two supplements most commonly used to raise NAD+ levels, NMN and NR, are marketed with claims that outrun the evidence. Here is a rigorous, up-to-date look at what we actually know.
✓ Cited Sources
- NAD+ levels decline approximately 50% between ages 40 and 60 in most human tissues, reducing the activity of NAD+-dependent enzymes (sirtuins, PARPs) that are central to DNA repair, epigenetic regulation, and mitochondrial function.
- Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) effectively raise blood NAD+ levels in humans. The clinical significance of this elevation remains an active area of research.
- Human trials to date are small (n = 12–60), short-duration (8–12 weeks), and focused on surrogate endpoints (blood NAD+ levels, insulin sensitivity) rather than hard longevity outcomes. No long-term human longevity data exists for either compound.
- The weight of current evidence slightly favors NMN over NR in terms of tissue-specific delivery — particularly to muscle, where NR may not efficiently convert — but this remains contested in the literature.
- The most important determinant of NAD+ levels is not supplementation — it is lifestyle. Exercise, particularly endurance exercise, raises NAD+ via AMPK activation and NRK1/2 pathways. Addressing NAD+ drainage through excess alcohol, chronic inflammation, and DNA damage is foundational.
In 2013, David Sinclair's lab at Harvard published research showing that restoring NAD+ levels in aged mice reversed multiple markers of aging — muscle atrophy, metabolic dysfunction, mitochondrial decline — within weeks. The findings were extraordinary, and they lit a fire under the supplement industry. Today, NMN and NR are among the fastest-growing products in the longevity supplement market, generating hundreds of millions in annual sales.
But the mice were not people. And the two years since Sinclair's paper have produced a more nuanced, more complicated, and more honest picture of what NAD+ supplementation actually does in humans. This article synthesizes that evidence — including the most recent clinical trials — to give you the clearest possible view of what these supplements can and cannot do.[1]
Why NAD+ Matters: The Mechanistic Case
NAD+ is a coenzyme found in every cell of the body, essential to hundreds of metabolic reactions. It serves two primary roles: as an electron carrier in energy metabolism (the NAD+/NADH redox couple at the heart of the Krebs cycle and oxidative phosphorylation), and as a substrate for a class of NAD+-consuming signaling enzymes — primarily sirtuins and PARPs — that regulate some of the most important longevity-relevant processes in biology.[2]
The seven sirtuins (SIRT1–7) use NAD+ to remove acetyl groups from proteins, thereby regulating gene expression, mitochondrial function, inflammation, and DNA repair. SIRT1 and SIRT3 are particularly important for longevity — their activity declines with age, and this decline is at least partially attributable to falling NAD+ levels. PARP enzymes, which repair DNA strand breaks, also consume large quantities of NAD+. As DNA damage accumulates with age, PARP activity increases — draining NAD+ and further reducing sirtuin activity in a vicious cycle.[3]
This mechanistic chain — NAD+ decline → reduced sirtuin and PARP activity → accelerated epigenetic aging, impaired DNA repair, mitochondrial dysfunction — is compelling and internally consistent. It is why NAD+ precursors have attracted so much scientific attention. The question is whether supplementing NAD+ precursors in humans actually activates this pathway in clinically meaningful ways.
NMN and NR: The Key Differences
Both NMN and NR are NAD+ precursors — molecules that the body converts into NAD+. NR (nicotinamide riboside) is converted to NMN by the enzyme NRK1/2, which then enters the NAD+ biosynthesis pathway. NMN (nicotinamide mononucleotide) enters the pathway one step further downstream — closer to NAD+ — and may be transported into cells via the Slc12a8 transporter, which is expressed in the small intestine and some other tissues.[4]
The theoretical advantage of NMN is that it bypasses the NRK1/2 conversion step, potentially allowing more efficient NAD+ production in tissues where NRK1/2 activity is limiting. The theoretical advantage of NR is that it has been studied longer in humans, has more published clinical trial data, and is generally less expensive.
| Characteristic | NMN | NR |
|---|---|---|
| Molecular weight | 334 g/mol | 255 g/mol |
| Steps to NAD+ | 1 step | 2 steps |
| Human trials (published) | ~8 trials | ~14 trials |
| Blood NAD+ raising effect | Comparable / slightly higher | Comparable |
| Muscle NAD+ delivery | Evidence of direct uptake | Less clear in some studies |
| Cost (typical 500mg/day) | $60–$100/month | $40–$70/month |
| Long-term safety data | Limited (<1 year) | Slightly more |
| Oral bioavailability | High (sublingual may be superior) | High |
What Human Trials Actually Show
Before reviewing the trial data, a critical caveat: the human evidence base for both NMN and NR is still in its early stages. Most published trials are small, short, and focused on intermediate biomarkers rather than clinical outcomes. No randomized controlled trial has demonstrated that either compound extends human lifespan or meaningfully reduces age-related disease incidence. Extrapolating from mouse data or surrogate endpoints to longevity claims requires enormous epistemic caution.[5]
NR: The More-Studied Compound
The strongest NR human data comes from Charles Brenner's group at University of Iowa and ChromaDex-sponsored trials. Key findings include: NR (250–1000mg/day) consistently raises blood NAD+ levels in a dose-dependent manner (40–90% increase over baseline). A 2018 trial in healthy middle-aged adults found NR supplementation raised NAD+ in blood and muscle.[6] However, functional outcomes — insulin sensitivity, muscle function, inflammation, blood pressure — have been inconsistently improved across trials, with several high-quality trials showing no significant benefit on these endpoints despite confirmed NAD+ elevation.[7]
NMN: The Newer Contender
A landmark 2021 trial by Yoshino et al. at Washington University provided the most rigorous NMN human data to date. In a double-blind RCT of 25 overweight postmenopausal women, NMN (250mg/day × 10 weeks) increased muscle NAD+ levels and improved insulin signaling in skeletal muscle — effects not seen in the placebo group. The trial was small but well-designed, and represented the first direct demonstration of muscle-tissue NAD+ elevation from oral NMN in humans.[8]
A 2022 Japanese trial in healthy older adults found NMN (250mg/day × 12 weeks) improved walking speed and grip strength modestly — intriguing findings that warrant replication in larger trials.[9]
A 2023 paper raised an important concern: raising NAD+ levels via supplementation may not effectively reach all tissues equally. Brain and liver NAD+ may be poorly responsive to oral NMN/NR due to limited precursor transport across cell membranes in these tissues. This does not negate the potential benefits in muscle, blood, and other accessible tissues, but it should temper claims about brain health benefits specifically. Research into tissue-targeted NAD+ delivery is ongoing.
The Lifestyle Foundation: Don't Supplement Over a Broken Foundation
The most consistent and powerful ways to raise NAD+ levels remain lifestyle interventions, not supplements. This does not diminish the potential role of NMN or NR — it contextualizes it.
Exercise robustly raises NAD+ via AMPK activation, which upregulates NAMPT (the rate-limiting enzyme in NAD+ biosynthesis). Endurance training increases NAMPT expression in skeletal muscle, the primary tissue where NAD+ metabolism matters most for longevity.[10]
Caloric restriction and fasting reduce NAD+ consumption by limiting the DNA damage (via PARP activation) and inflammation that drain the NAD+ pool. They also upregulate SIRT1 activity independently of NAD+ levels.
Reducing alcohol is particularly important: alcohol metabolism consumes NAD+ directly (via alcohol dehydrogenase) and generates acetaldehyde that damages DNA — increasing PARP-mediated NAD+ drainage. Heavy drinking can substantially deplete NAD+ independent of aging.
Who Should Consider NMN or NR?
Given the current evidence, the strongest case for NAD+ supplementation exists in: people over 50 whose lifestyle is already optimized (exercise, diet, sleep, stress management); people with confirmed metabolic dysfunction (insulin resistance, type 2 diabetes) where muscle NAD+ depletion is mechanistically implicated; and people with conditions that dramatically increase NAD+ consumption (inflammatory diseases, active DNA repair demands). For healthy people under 40 with good lifestyle habits, the marginal benefit is likely small and the cost-benefit analysis less favorable.[11]
References
- 1Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624-1638.
- 2Cantó C, et al. "NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus." Cell Metabolism. 2015.
- 3Imai S, Guarente L. "NAD+ and sirtuins in aging and disease." Trends in Cell Biology. 2014;24(8):464-471.
- 4Grozio A, et al. "Slc12a8 is a nicotinamide mononucleotide transporter." Nature Metabolism. 2019;1(1):47-57.
- 5Fang EF, et al. "NAD+ in aging: molecular mechanisms and translational implications." Trends in Molecular Medicine. 2017.
- 6Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications. 2018.
- 7Dollerup OL, et al. "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects." American Journal of Clinical Nutrition. 2018.
- 8Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224-1229.
- 9Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and enables muscle function." npj Aging. 2022.
- 10Canto C, et al. "AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity." Nature. 2009.
- 11Nadeeshani H, et al. "Nicotinamide mononucleotide (NMN) as an anti-aging health product — Promises and safety concerns." Journal of Advanced Research. 2022.